Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4% - Time to Sell?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) traded down 5.4% during trading on Monday . The company traded as low as $14.22 and last traded at $14.29. 41,054 shares changed hands during trading, a decline of 75% from the average session volume of 165,199 shares. The stock had previously closed at $15.10.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARTV. Jefferies Financial Group began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a "buy" rating and a $21.00 target price on the stock. Wedbush reiterated an "outperform" rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 target price on the stock. TD Cowen began coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a "buy" rating on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artiva Biotherapeutics presently has an average rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Down 12.0 %

The business's fifty day simple moving average is $12.23.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Thursday, August 29th. The company reported ($19.10) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($18.03). On average, analysts forecast that Artiva Biotherapeutics, Inc. will post -4.6 earnings per share for the current year.

Insider Transactions at Artiva Biotherapeutics

In related news, Director Yong-Jun Huh purchased 2,083,332 shares of Artiva Biotherapeutics stock in a transaction dated Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the acquisition, the director now directly owns 3,306,900 shares in the company, valued at approximately $39,682,800. The trade was a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Global Strategic Fund I. Venbio purchased 416,666 shares of Artiva Biotherapeutics stock in a transaction dated Monday, July 22nd. The shares were acquired at an average price of $12.00 per share, for a total transaction of $4,999,992.00. Following the acquisition, the insider now directly owns 1,936,637 shares in the company, valued at approximately $23,239,644. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Yong-Jun Huh purchased 2,083,332 shares of Artiva Biotherapeutics stock in a transaction dated Monday, July 22nd. The shares were bought at an average price of $12.00 per share, for a total transaction of $24,999,984.00. Following the acquisition, the director now owns 3,306,900 shares in the company, valued at approximately $39,682,800. This trade represents a 100.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.